There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Guardant Health (GH – Research Report), ...

Analysts at B. Riley raised their Q1 2025 earnings per share estimates for Madrigal Pharmaceuticals in a research report issued on Thursday, February 27th. B. Riley analyst M. Mamtani now expects that ...

B. Riley upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Thursday morning, Marketbeat ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern. The sentiment among these major traders is split, with 44% bullish and 44% bearish.

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a ...

Over the last 7 days, the United States market has experienced a 3.6% drop, yet it remains up by 17% over the past year with earnings forecasted to grow by 14% annually. In this context of fluctuating ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch ...

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price ...

Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money ...